Stockscreener 앱 받기
3.32
3.49%
-0.12
시간 외 거래:
3.38
0.06
+1.81%
전일 마감가:
$3.44
열려 있는:
$3.42
하루 거래량:
57,646
Relative Volume:
0.16
시가총액:
$21.24M
수익:
-
순이익/손실:
$-31.97M
주가수익비율:
-0.4019
EPS:
-8.2612
순현금흐름:
$-5.66M
1주 성능:
-8.29%
1개월 성능:
-22.07%
6개월 성능:
-56.32%
1년 성능:
-59.90%
1일 변동 폭
$3.2805
$3.43
1주일 범위
$3.21
$3.71
52주 변동 폭
$2.07
$15.96
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.32 | 22.01M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quantum Biopharma Ltd 주식(QNTM)의 최신 뉴스
QNTM Should I Buy - Intellectia AI
Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast - TradingView
Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study - TipRanks
Quantinuum (QNTM) Receives Strong Ratings, Shares Rise 5% in Pre-Market - GuruFocus
Quantum Biopharma Q4 2025 Earnings: Reports net loss of $0.71 per share as clinical‑stage biotech continues operationsFinancial Summary - dars.gov.et
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (BOATS:QNTM) - TradingView
QNTM Forecast — Price Target — Prediction for 2027 - TradingView
Quantum BioPharma Reaches Midpoint in MS Imaging Study, Early Results Show Promise - citybuzz -
Quantum BioPharma's Lucid-MS Targets Underlying Cause of Multiple Sclerosis in Growing $38.6B Market - citybuzz -
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) the - GlobeNewswire
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (NASDAQ:QNTM) - TradingView
Quantum BioPharma Ltd (QNTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quantum BioPharma’s Lucid-MS Aims to Fill Void in Multiple Sclerosis Treatment - citybuzz -
Quantum BioPharma’s MS drug targets myelin as phase 2 nears - Stock Titan
Quantum BioPharma Company Profile & Introduction - Moomoo
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis - citybuzz -
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Cash Flow – HAM:0K91 - TradingView
The Quest to Repair What Multiple Sclerosis Takes Away - Caledon Enterprise
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach - Sahm
Quantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - TipRanks
Quantum BioPharma's Lucid-MS Candidate Highlighted for Potential to Address Unmet Need in Multiple Sclerosis Treatment - citybuzz -
Quantum BioPharma's Bid to Repair MS, Not Just Manage It - BriefGlance
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, - GlobeNewswire
QNTM News | QUANTUM BIOPHARMA-B SUB VOT (NASDAQ:QNTM) - ChartMill
Quantum BioPharma Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials - citybuzz -
Quantum BioPharma Ltd (QNTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quantum BioPharma Ltd (QNTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quantum BioPharma Ltd (QNTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quantum BioPharma Ltd (QNTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quantum BioPharma Ltd (QNTM) Institutional Confidence - TradingKey
Quantum BioPharma Ltd (QNTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quantum BioPharma Ltd (QNTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
QNTM Q4 2025 Earnings: Net Loss Widens as Biotech Advances Pipeline Without RevenueCapex Guidance - lwvtexas.org
Quantum Biopharma Ltd. (QNTM) Q4 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss per Share; Stock Gains $1.78GAAP Earnings Report - newsline.com
QNTM Q4 2025 Earnings: Loss per Share Reported as Revenue Remains UnreportedMid-Term Outlook - dars.gov.et
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for MS Treatment - TradingView
CSE Filings for Quantum BioPharma Ltd. - The Canadian Securities Exchange (CSE)
Quantum BioPharma Advances Lucid-MS Therapy for Multiple Sclerosis After Positive Phase 1 Trial - citybuzz -
Quantum BioPharma Ltd. - The Canadian Securities Exchange (CSE)
Quantum BioPharma Ltd. Subordinate Voting Shares - The Canadian Securities Exchange (CSE)
Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd™ Growth Opportunities on BioMedWire Podcast - NewMediaWire
Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast - TipRanks
Quantum Biopharma Ltd (QNTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):